Famprofazone
Famprofazone (Gewodin, Gewolen) is a nonsteroidal anti-inflammatory agent (NSAID) of the pyrazolone series which is available over-the-counter in some countries such as Taiwan.[1][2][3] It has analgesic, anti-inflammatory, and antipyretic effects.[1][2] Famprofazone has been known to produce methamphetamine as an active metabolite, with 15-20% of an oral dose being converted to it.[4][5] As a result, famprofazone has occasionally been implicated in causing positives on drug tests for amphetamines.[3]
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.041.153 |
Chemical and physical data | |
Formula | C24H31N3O |
Molar mass | 377.532 g·mol−1 |
3D model (JSmol) | |
|
See also
References
- Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. p. 1932. ISBN 3-88763-075-0.
- Hall, Judith A.; Morton, Ian (1999). Concise dictionary of pharmacological agents: properties and synonyms. Kluwer Academic. p. 342. ISBN 0-7514-0499-3.
- Chan KH, Hsu MC, Tseng CY, Chu WL (2010). "Famprofazone use can be misinterpreted as methamphetamine abuse". Journal of Analytical Toxicology. 34 (6): 347–53. doi:10.1093/jat/34.6.347. PMID 20663288.
- Oh ES, Hong SK, Kang GI (March 1992). "Plasma and urinary concentrations of methamphetamine after oral administration of famprofazone to man". Xenobiotica. 22 (3): 377–84. doi:10.3109/00498259209046649. PMID 1496827.
- Shin HS, Park BB, Choi SN, Oh JJ, Hong CP, Ryu H (1998). "Identification of new urinary metabolites of famprofazone in humans". Journal of Analytical Toxicology. 22 (1): 55–60. doi:10.1093/jat/22.1.55. PMID 9491970.
pyrazolones / pyrazolidines | |
---|---|
salicylates | |
acetic acid derivatives and related substances | |
oxicams |
|
propionic acid derivatives (profens) |
|
n-arylanthranilic acids (fenamates) | |
COX-2 inhibitors (coxibs) | |
other | |
NSAID combinations | |
Key: underline indicates initially developed first-in-class compound of specific group; #WHO-Essential Medicines; †withdrawn drugs; ‡veterinary use. | |
DRAsTooltip Dopamine releasing agents |
| ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NRAsTooltip Norepinephrine releasing agents |
| ||||||||||||||
SRAsTooltip Serotonin releasing agents |
| ||||||||||||||
Others |
| ||||||||||||||
See also: Receptor/signaling modulators • Monoamine reuptake inhibitors • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins |
CARTooltip Constitutive androstane receptor |
|
---|---|
PXRTooltip Pregnane X receptor |
|
|
Phenethylamines |
|
---|---|
Amphetamines |
|
Phentermines |
|
Cathinones |
|
Phenylisobutylamines | |
Phenylalkylpyrrolidines | |
Catecholamines (and close relatives) |
|
Miscellaneous |
|
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.